Immunosuppressant agents and liver transplantion at COVID۱۹ pandemic

Background and Aim : It seems that transplant recipients are at high risk for severe COVID-۱۹, especially in the presence of comorbidities and immunosuppression. This study aimed to determine the effects of previous treatment with immunosuppressants and received dosage and the risk of COVID-۱۹ severity and mortality in liver transplant recipients in various post-transplantation phases in the Iranian population Methods : This was a cross-sectional study conducted among ۲۴ patients undergone liver transplantation, who were referred to two transplant centers (Imam Reza and Montaseriyeh hospitals) affiliated to Mashhad University of Medical silences, Mashhad, Iran, during ۲۰۲۰-۲۰۲۱. The demographic and clinical characteristics of the patients were recorded in a checklist and the relationships between various variables were analyzedResults : The majority of the patients (۹۶%) were in the late phase of post-transplantation, and ۸.۳% of the cases expired. COVID-۱۹ severity and mortality did not show a significant relationship with previous treatment with immunosuppressants and received dosage (P>۰.۰۵). In addition, there was no relationship between the symptoms of COVID-۱۹ and immunosuppressant dosages, except for headache. No significant correlation was found between immunosuppressants dosage and laboratory findings, and only prednisolone dosage was found to be correlated with heart rate (r=-۰.۶۲, P=۰.۰۳), BUN (r=-۰.۸۴, P=۰.۰۰۲), and D-dimer (r=-۰.۷۲, P=۰.۰۱)Conclusion : Severe SARS‐CoV‐۲ infection was reported in the majority of liver transplant recipients. The severity of COVID-۱۹ was not related to previous treatment with immunosuppressants and received dosage

Keywords:

COVID‐۱۹ , Immunosuppressive , Mortality , Transplantation